{
  "abstract": "Background\n\nDespite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.Objectives\n\nTo evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).Methods\n\nPsychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.Results\n\nFor the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from r = 0.51-0.72, comparable to the UMSARS Total score (r = 0.49-0.69) and higher than UMSARS Part I (r = 0.42-0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64-2.92) and lower in no-change groups (0.97-1.62).Conclusions\n\nThe modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.",
  "abstract_shown": true,
  "affiliations": [
    "H. Lundbeck A/S, DK-2500 Valby, Copenhagen, Denmark."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Anna-Karin Berger",
      "orcid": "0000-0002-4997-3474"
    },
    {
      "affs": [
        0
      ],
      "name": "Andreas Rieckmann"
    },
    {
      "affs": [
        0
      ],
      "name": "Krishan Nighah"
    },
    {
      "affs": [
        0
      ],
      "name": "Stefano Zanigni"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/434sgd09nem39.bib",
  "cited_by": 0,
  "doi": "10.1016/j.prdoa.2026.100510",
  "fulltext_url": "https://europepmc.org/articles/PMC13694933",
  "id": "434sgd09nem39",
  "issns": [
    "2590-1125"
  ],
  "landing_url": "https://europepmc.org/article/MED/42927221",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7221719647",
  "pdf_url": "https://europepmc.org/articles/PMC13694933?pdf=render",
  "pmcid": "PMC13694933",
  "pmid": "42927221",
  "published": "2026-10-13",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/434sgd09nem39.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42927221",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42927221"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Parkinson's Disease Mechanisms and Treatments",
      "subfield": "neurology"
    }
  ],
  "title": "Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale.",
  "title_text": "Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/434sgd09nem39",
  "venue": "Clinical parkinsonism & related disorders",
  "versions": []
}